A New B-Raf Inhibitor Combo for Advanced Melanoma

Oncotarget - United States
doi 10.18632/oncotarget.26171
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

FOXD3 Is a Mutant B-Raf-Regulated Inhibitor of G1-S Progression in Melanoma Cells

Cancer Research
Cancer ResearchOncology
2010English

Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Cancer Research
Cancer ResearchOncology
2013English

Combinatorial Therapies to Overcome B-Raf Inhibitor Resistance in Melanomas

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2012English

Targeting Mutant (V600E) B-Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation

Cancer Research
Cancer ResearchOncology
2007English

Metabolic Imaging Using Hyperpolarized 13 C‐pyruvate to Assess Sensitivity to the B‐Raf Inhibitor Vemurafenib in Melanoma Cells and Xenografts

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

BCL2/MDM2 Inhibitor Combo Effective in AML

Cancer Discovery
Oncology
2019English

Utility of Circulating B-Raf DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2007English

Evaluation of the Immunologic Impact of RAF Inhibitors to Guide Optimal Combination of RAF Inhibitors and Immunotherapy for the Treatment of Advanced Melanoma

2014English

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy